Paediatric mycosis fungoides - characteristics, management and outcomes with particular focus on the folliculotropic variant.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
revised:
22
11
2021
received:
15
08
2021
accepted:
07
12
2021
pubmed:
27
1
2022
medline:
15
4
2022
entrez:
26
1
2022
Statut:
ppublish
Résumé
The literature on paediatric mycosis fungoides (MF) and especially its folliculotropic variant (FMF) is sparse. To describe the clinical manifestations, treatments, outcomes and long-term course of paediatric MF, including FMF. A retrospective analysis was conducted of all consecutive MF patients diagnosed at ≤18 years attending two medical centres in 1995-2015. The cohort included 71 patients, all but two of whom had early-stage disease: hypopigmented (55%), folliculotropic (42%) and classical MF (39%), alone or in combination. The head and neck area were involved in 43% of patients with early-stage FMF compared to 12% of the non-FMF group (P = 0.004). There was no difference in the involvement of other body areas between the groups. Pruritus, although mild, was more often recorded among patients with early-stage FMF compared to non-FMF (58% vs. 29%, respectively, P = 0.02). Complete response (CR) was achieved in 60 of the 69 patients with early-stage MF (87%) after an average of 1.8 treatment modalities. NBUVB was the most administered treatment to non-FMF patients with CR rates of 63% vs. 29% of FMF patients (P = 0.04). Systemic/bath PUVA and UVA+NBUVB were the most administered treatments to FMF patients with CR rates of 60% vs. 81% for non-FMF patients (P = 0.17). During a mean follow-up of 9.2 years (range 1-24), stage progression was observed in four (6%) of the patients with early-stage disease, two of whom (all FMF) to advanced stage. Paediatric MF presents as an early-stage disease with over-representation of hypopigmented and FMF variants. NBUVB and UVA-based therapies yield good response rates in non-FMF and FMF patients, respectively. Disease course is indolent, and even on relatively long follow-up, it has a very low progression rate from early to advanced-stage disease, occurring in patients with FMF. We propose a treatment algorithm for paediatric MF.
Sections du résumé
BACKGROUND
BACKGROUND
The literature on paediatric mycosis fungoides (MF) and especially its folliculotropic variant (FMF) is sparse.
OBJECTIVES
OBJECTIVE
To describe the clinical manifestations, treatments, outcomes and long-term course of paediatric MF, including FMF.
METHODS
METHODS
A retrospective analysis was conducted of all consecutive MF patients diagnosed at ≤18 years attending two medical centres in 1995-2015.
RESULTS
RESULTS
The cohort included 71 patients, all but two of whom had early-stage disease: hypopigmented (55%), folliculotropic (42%) and classical MF (39%), alone or in combination. The head and neck area were involved in 43% of patients with early-stage FMF compared to 12% of the non-FMF group (P = 0.004). There was no difference in the involvement of other body areas between the groups. Pruritus, although mild, was more often recorded among patients with early-stage FMF compared to non-FMF (58% vs. 29%, respectively, P = 0.02). Complete response (CR) was achieved in 60 of the 69 patients with early-stage MF (87%) after an average of 1.8 treatment modalities. NBUVB was the most administered treatment to non-FMF patients with CR rates of 63% vs. 29% of FMF patients (P = 0.04). Systemic/bath PUVA and UVA+NBUVB were the most administered treatments to FMF patients with CR rates of 60% vs. 81% for non-FMF patients (P = 0.17). During a mean follow-up of 9.2 years (range 1-24), stage progression was observed in four (6%) of the patients with early-stage disease, two of whom (all FMF) to advanced stage.
CONCLUSIONS
CONCLUSIONS
Paediatric MF presents as an early-stage disease with over-representation of hypopigmented and FMF variants. NBUVB and UVA-based therapies yield good response rates in non-FMF and FMF patients, respectively. Disease course is indolent, and even on relatively long follow-up, it has a very low progression rate from early to advanced-stage disease, occurring in patients with FMF. We propose a treatment algorithm for paediatric MF.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
671-679Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2022 European Academy of Dermatology and Venereology.
Références
Jung JM, Lim DJ, Won CH, Chang SE, Lee MW, Lee WJ. Mycosis fungoides in children and adolescents: a systematic review. JAMA Dermatol 2021; 157: 431.
Criscione VD, Weinstock MA. Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002. Arch Dermatol 2007; 143: 854-859.
Assaf C, Gellrich S, Steinhoff M et al. Cutaneous lymphomas in Germany: an analysis of the Central Cutaneous Lymphoma Registry of the German Society of Dermatology (DDG). J Dtsch Dermatol Ges 2007; 5: 662-668.
van Doorn R, Van Haselen CW, van Voorst Vader PC et al. Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients. Arch Dermatol 2000; 136: 504-510.
Fatemi Naeini F, Abtahi-Naeini B, Sadeghiyan H, Nilforoushzadeh MA, Najafian J, Pourazizi M. Mycosis fungoides in Iranian population: an epidemiological and clinicopathological study. J Skin Cancer 2015; 2015: 306543.
Nanda A, Alsaleh QA, Al-Ajmi H et al. Mycosis fungoides in arab children and adolescents: a report of 36 patients from Kuwait. Pediatr Dermatol 2010; 27: 607-613.
Tan EST, Tang MBY, Tan SH. Retrospective 5-year review of 131 patients with mycosis fungoides and Sezary syndrome seen at the National Skin Centre, Singapore. Australas J Dermatol 2006; 47: 248-252.
Yazganoglu KD, Topkarci Z, Buyukbabani N, Baykal C. Childhood mycosis fungoides: a report of 20 cases from Turkey. J Eur Acad Dermatol Venereol 2013; 27: 295-300.
Hodak E, Amitay-Laish I, Feinmesser M et al. Juvenile mycosis fungoides: cutaneous T-cell lymphoma with frequent follicular involvement. J Am Acad Dermatol 2014; 70: 993-1001.
Wain EM, Orchard GE, Whittaker SJ, Spittle MF, Russell-Jones R. Outcome in 34 patients with juvenile-onset mycosis fungoides: a clinical, immunophenotypic, and molecular study. Cancer 2003; 98: 2282-2290.
Pope E, Weitzman S, Ngan B et al. Mycosis fungoides in the pediatric population: report from an international childhood registry of cutaneous lymphoma. J Cutan Med Surg 2010; 14: 1-6.
Kim S-T, Sim H-J, Jeon Y-S et al. Clinicopathological features and T-cell receptor gene rearrangement findings of mycosis fungoides in patients younger than age 20 years. J Dermatol 2009; 36: 392-402.
Fink-Puches R, Chott A, Ardigó M et al. The spectrum of cutaneous lymphomas in patients less than 20 years of age. Pediatr Dermatol 2004; 21: 525-533.
Tan E, Tay YK, Giam YC. Profile and outcome of childhood mycosis fungoides in Singapore. Pediatr Dermatol 2000; 17: 352-356.
Pabsch H, Rütten A, Von Stemm A, Meigel W, Sander CA, Schaller J. Treatment of childhood mycosis fungoides with topical PUVA. J Am Acad Dermatol 2002; 47: 557-561.
Ben-Amitai D, David M, Feinmesser M, Hodak E. Juvenile mycosis fungoides diagnosed before 18 years of age. Acta Derm Venereol 2003; 83: 451-456.
Moon HR, Lee WJ, Won CH et al. Paediatric cutaneous lymphoma in Korea: a retrospective study at a single institution. J Eur Acad Dermatol Venereol 2014; 28: 1798-1804.
Willemze R, Jaffe ES, Burg G et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768-3785.
Hodak E, Amitay-Laish I, Atzmony L et al. New insights into folliculotropic mycosis fungoides (FMF): a single-center experience. J Am Acad Dermatol 2016; 75: 347-355.
van Santen S, Roach REJ, van Doorn R et al. Clinical staging and prognostic factors in folliculotropic mycosis fungoides. JAMA Dermatol 2016; 152: 992-1000.
Olsen EA, Whittaker S, Kim YH et al. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the E. J Clin Oncol 2011; 29: 2598-2607.
Quaglino P, Pimpinelli N, Berti E et al. Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classic mycosis fungoides: a multicenter, retrospective follow-up study from the Italian Group of Cutaneous Lymphomas. Cancer 2012; 118: 5830-5839.
Talpur R, Singh L, Daulat S et al. Long-term outcomes of 1,263 patients with mycosis fungoides and Sézary syndrome from 1982 to 2009. Clin Cancer Res 2012; 18: 5051-5060.
Agar NS, Wedgeworth E, Crichton S et al. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol 2010; 28: 4730-4739.
van Santen S, van Doorn R, Neelis KJ et al. Recommendations for treatment in folliculotropic mycosis fungoides: report of the Dutch cutaneous lymphoma group. Br J Dermatol 2017; 177: 223-228.
Amitay-Laish I, Prag-Naveh H, Dalal A, Pavlovsky L, Feinmesser M, Hodak E. Treatment of early folliculotropic mycosis fungoides with special focus on psoralen plus ultraviolet A. Acta Derm Venereol 2018; 98: 951-955.
Olsen EA, Hodak E, Anderson T et al. Guidelines for phototherapy of mycosis fungoides and Sézary syndrome: a consensus statement of the United States Cutaneous Lymphoma Consortium. J Am Acad Dermatol 2016; 74: 27-58.
Pavlotsky F, Hodak E, Ben Amitay D, Barzilai A. Role of bath psoralen plus ultraviolet A in early-stage mycosis fungoides. J Am Acad Dermatol 2014; 71: 536-541.
Pavlotsky F, Dawood M, Barzilai A. Potential of narrow-band ultraviolet B to induce sustained durable complete remission off-therapy in patients with stage I mycosis fungoides. J Am Acad Dermatol 2019; 80: 1550-1555.
Wernham AG, Shah F, Amel-Kashipaz R, Cobbold M, Scarisbrick J. Stage I mycosis fungoides: frequent association with a favourable prognosis but disease progression and disease-specific mortality may occur. Br J Dermatol 2015; 173: 1295-1297.